Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

AI Briefing

• – Dyne Therapeutics initiates Phase 3 HARMONIA trial of z-basivarsen for Myotonic Dystrophy Type 1
• – The trial will evaluate z-basivarsen's efficacy, safety and tolerability in DM1 patients
• – The HARMONIA trial is a multi-system study